Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer

References

• Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization classification of tumours: Pathology and genetics of tumours of the lung, pleura, thymus and heart. Kleihues P, Sobin LH, editors. Lyon, France: IARC Press, International Agency for Research on Cancer; 2004.
   Google Scholar
• Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting outcomes in radiation oncology – multifactorial decision support systems. Nat Rev Clin Oncol 2013;10:27–40.
   PubMed Web of Science ®Google Scholar
• Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: Extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441–6.
   PubMed Web of Science ®Google Scholar
• Salminen E, Mac Manus M. Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer. Ann Med 2001;33:404–9.
   PubMed Web of Science ®Google Scholar
• Fuss M. Strategies of assessing and quantifying radiation treatment metabolic tumor response using F18 FDG Positron Emission Tomography (PET). Acta Oncol 2010; 49:948–55.
   PubMed Web of Science ®Google Scholar
• Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?J Nucl Med 2013;54:19–26.
   PubMed Web of Science ®Google Scholar
• Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging 2013;40:290–301.
   PubMed Web of Science ®Google Scholar
• Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, et al. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg 2013;257: 364–70.
   PubMed Web of Science ®Google Scholar
• Soussan M, Chouahnia K, Maisonobe JA, Boubaya M, Eder V, Morere JF, et al. Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy. Eur J Nucl Med Mol Imaging Epub 2013 Jan 11.
   Google Scholar
• ICRU Report 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Bethesda, MD: International Commission on Radiation Units and Measurements 1993.
   Google Scholar
• Oncology MR. Radiotherapy for NSCLC to a Individualized MLD (BRONC MLD). 2010 [updated 2013 April 29]; Available from: http://clinicaltrials.gov/show/NCT00573040.
   Google Scholar
• Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35:2320–33.
   PubMed Web of Science ®Google Scholar
• Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1): 122S–150S.
   PubMed Web of Science ®Google Scholar
• Drzymala RE, Mohan R, Brewster L, Chu J, Goitein M, Harms W, et al. Dose-volume histograms. Int J Radiat Oncol Biol Phys 1991;21:71–8.
   PubMed Web of Science ®Google Scholar
• Deasy JO, Blanco AI, Clark VH. CERR: A computational environment for radiotherapy research. Med Phys 2003;30: 979–85.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon J, Houben R, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386–92.
   PubMed Web of Science ®Google Scholar
• Kauppi JT, Oksala N, Salo JA, Helin H, Karhumaki L, Kemppainen J, et al. Locally advanced esophageal adenocarcinoma: Response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol 2012; 51:636–44.
   PubMed Web of Science ®Google Scholar
• Velazquez ER, Aerts HJ, Oberije C, De Ruysscher D, Lambin P. Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol 2010;49:1033–9.
   PubMed Web of Science ®Google Scholar
• Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, et al. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. Lung Cancer 2012;78:219–24.
   PubMed Web of Science ®Google Scholar
• Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging 2010;37:691–8.
   PubMed Web of Science ®Google Scholar
• Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, 2nd, Patz EF, Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non- small-cell lung carcinoma. J Clin Oncol 2008;26: 1459–64.
   PubMed Web of Science ®Google Scholar
• Vanderhoek M, Perlman SB, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med 2012;53:4–11.
   PubMed Web of Science ®Google Scholar
• El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit 2009;42:1162–71.
   PubMed Web of Science ®Google Scholar
• van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging 2011;38:1636–47.
   PubMed Web of Science ®Google Scholar